Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Alkon’s test is just one in a number of new approaches to early detection, including measuring molecules linked to the disease in blood and cerebrospinal fluid, as well as new brain-imaging markers that can detect signs of Alzheimer’s, such as buildup of the protein beta-amyloid–a hallmark of the disease. “A number of these tests have been successful in separating Alzheimer’s patients from normal subjects, but most of them have not as yet compared those with AD to those with other neurological diseases, such as ALS,” says Gilman.

The new research is “interesting and promising, but we need to know how specific it will turn out to be,” he says. “There is a history of tests that are in the news and then disappear quietly.”

Alkon says that the skin test can distinguish between other types of neurological diseases, such as Parkinson’s, Huntington’s, and Lewy body disease–a finding that he aims to confirm in larger clinical trials. He also hopes to confirm the test’s ability to diagnose Alzheimer’s early on–within four years of when a patient first notices memory problems. Clinical diagnosis within this period can be hit or miss, with accuracy rates as low as 55 percent.

Alkon is also planning a small clinical trial of an experimental drug called bryostatin, originally tested as an anticancer drug, for Alzheimer’s. At low concentrations, the drug activates PKCs. Developing drugs that target PKCs has been somewhat difficult because some can trigger the formation of tumors. But Alkon says that he has identified structural variations in these molecules that predict which ones potentially cause tumors. His team has developed a number of novel PKC-activating compounds, which he eventually hopes to test in clinical trials.

0 comments about this story. Start the discussion »

Credit: Blanchette Rockefeller Neurosciences Institute

Tagged: Biomedicine, brain, diagnostics, diseases, Alzheimer's, enzymes, skin cells

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me
×

A Place of Inspiration

Understand the technologies that are changing business and driving the new global economy.

September 23-25, 2014
Register »